Oragenics (NYSE:OGEN) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research note issued to investors on Saturday. The brokerage issued a sell rating on the stock.

Oragenics Price Performance

Shares of OGEN opened at $0.29 on Friday. The firm has a market cap of $3.51 million, a P/E ratio of -0.04 and a beta of 0.38. Oragenics has a 1 year low of $0.25 and a 1 year high of $4.00. The stock has a 50 day simple moving average of $0.33 and a two-hundred day simple moving average of $0.52.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.